Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.

ABSTRACT:

Objectives

We explored efficacy and safety of IVIg as first-line treatment in patients with an idiopathic inflammatory myopathy.

Methods

In this investigator-initiated phase 2 open-label study, we included 20 adults with a newly diagnosed, biopsy-proven idiopathic inflammatory myopathy, and a disease duration of less than 9 months. Patients with IBM and prior use of immunosuppressants were excluded. The standard treatment regimen consisted of IVIg (Privigen) monotherapy for 9 weeks: a loading dose (2 g/kg body weight) and two subsequent maintenance doses (1 g/kg body weight) with a 3-week interval. The primary outcome was the number of patients with at least moderate improvement on the 2016 ACR/EULAR Total Improvement Score. Secondary outcomes included time to improvement, t

SUBMITTER: Lim J 

PROVIDER: S-EPMC8023983 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature